• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Arcadis (ENXTAM:ARCAD) Gains Pentagon PFAS Validation As Fair Value Stays In Focus

    Simply Wall St·08/14/2026 01:30:30
    Listen to the news

    Arcadis (ENXTAM:ARCAD) is back on investor radars after the U.S. Department of Defense Defense Innovation Unit issued a Success Memo validating its role in PFAS destruction technology alongside partner 374Water.

    See our latest analysis for Arcadis.

    Arcadis has attracted fresh attention as the Success Memo coincides with a 24.12% 1 month share price return and a 23.77% 3 month share price return, while the 5 year total shareholder return of 21.54% points to steadier long term progress.

    If this kind of momentum in infrastructure and environmental solutions interests you, it could be a good moment to widen your search with the 35 power grid technology and infrastructure stocks

    Bulls see Arcadis as underappreciated after the PFAS win and a strong recent share price run, while bears question how much is already in the price. Which side does the current valuation support next?

    Most Popular Narrative: 3.2% Undervalued

    Arcadis closed at €43.22, compared with a widely followed narrative fair value of €44.64. That small gap rests on some very specific long range assumptions.

    Accelerating demand for energy transition, climate adaptation, water management, and resilient infrastructure projects driven by policy clarity and investment commitments in North America and Europe is expected to translate to higher multi year backlog conversion and organic revenue growth in coming periods.

    Read the complete narrative. Read the complete narrative.

    Want to see what sits behind that fair value for Arcadis? It is based on shifting revenue mix, margin expansion and a very particular earnings path. The full narrative spells out the playbook.

    Result: Fair Value of €44.64 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you also need to factor in slower than hoped revenue trends and ongoing high spending on digital and workforce projects, which could pressure the Arcadis investment case.

    Find out about the key risks to this Arcadis narrative.

    Next Steps

    Does the mix of optimism and concern around Arcadis match your own view, or challenge it? Take a closer look at the full picture with the 2 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Arcadis?

    If Arcadis has sharpened your interest in targeted opportunities, do not stop here. A broader watchlist can help you spot opportunities that others overlook.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.